AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes
- 1 October 2010
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 400 (4), 745-751
- https://doi.org/10.1016/j.bbrc.2010.08.141
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin ReleaseEndocrinology, 2007
- Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapiesCurrent Medical Research and Opinion, 2007
- Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: Predominant localization in pancreatic polypeptide-secreting PP-cellsBiochemical and Biophysical Research Communications, 2006
- Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agentsCell Metabolism, 2006
- Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptorBiochemical and Biophysical Research Communications, 2005
- GIF biology and fat metabolismLife Sciences, 1999
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Glucagon-Like PeptidesDiabetes, 1998
- Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?Diabetes, 1994
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992